Drug Trial Radar · NCT06188520
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
55
Actual
Start
Dec 5, 2023
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
Conditions
- ER+ HER2- Advanced Breast Cancer
- High-grade Serous Ovarian Cancer (HGSOC)
Interventions
AZD8421Drug
CDK2 inhibitor
CamizestrantDrug
SERD
RibociclibDrug
CDK4/6 inhibitor
PalbociclibDrug
CDK4/6 inhibitor
AbemaciclibDrug
CDK4/6 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) as defined in the protocol.Time frame: From start of treatment until the end of DLT period, assessed up to 28 days.
- Incidence of AEs/SAEsTime frame: From start of treatment until the end of safety follow-up, approximately 18 months.
- Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.Time frame: From start of treatment until the end of safety follow-up, approximately 18 months.
- Discontinuation of AZD8421 due to toxicityTime frame: From start of treatment until the end of safety follow-up, approximately 18 months.
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
St Louis, Missouri
Research Site
Providence, Rhode Island
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
East Melbourne, Australia
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Pamplona, Spain
Research Site
Valencia, Spain
Research Site
Cambridge, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.